Stieger Bruno, Gao Bo
Department of Clinical Pharmacology and Toxicology, University Hospital, Rämistrasse 100, Zurich, 8091, Switzerland,
Clin Pharmacokinet. 2015 Mar;54(3):225-42. doi: 10.1007/s40262-015-0241-y.
Drug targets in the central nervous system (CNS) are numerous and important for drug therapy, e.g., of epilepsy or pain. Drugs and other xenobiotics as well as nutrients cannot freely cross the blood-brain barrier or freely enter cells across plasma membranes and therefore require transport systems. This overview summarizes the current knowledge on the expression of drug transporters in barriers shielding the CNS from the systemic circulation and as such controlling the pharmacokinetics of drugs in the CNS. The main drug transporter families covered are SLCO, SCL22A, ABCB, and ABCC, as genes of these families code for numerous drug transporters. While knowledge on messenger RNA expression in humans, rats, and mice is remarkable, there is clearly a gap in knowledge on the subcellular expression of transporters in specific cells in the CNS and in the barriers shielding the CNS from the systemic circulation. Recent methodologic developments including synthesis of drugs and endogenous substances for imaging will in the future allow the investigation of the function and physiologic role of transporters in the CNS including difficult-to-access systems such as the choroid plexus.
Clin Pharmacokinet. 2015-3
Dialogues Clin Neurosci. 2006
Adv Drug Deliv Rev. 2003-1-21
Orv Hetil. 2016-3-6
Expert Opin Drug Metab Toxicol. 2018-9-5
Naunyn Schmiedebergs Arch Pharmacol. 2025-1-14
Nutrients. 2024-9-2
J Cereb Blood Flow Metab. 2024-7
Mol Genet Genomic Med. 2024-3
Int J Mol Sci. 2023-8-8
Int J Mol Sci. 2022-2-23
Int J Mol Sci. 2021-4-3
Handb Exp Pharmacol. 2021
Pharmaceutics. 2020-10-14
Expert Opin Drug Metab Toxicol. 2014-11-7
Clin Ophthalmol. 2014-9-26
Drug Metab Dispos. 2014-12
Neurology. 2014-10-7
Front Endocrinol (Lausanne). 2014-6-24
Front Endocrinol (Lausanne). 2014-6-18